Format

Send to

Choose Destination
Medicine (Baltimore). 2016 May;95(22):e3830. doi: 10.1097/MD.0000000000003830.

Outcomes of 50 Patients With Ewing Sarcoma Family of Tumors Treated at a Single Institution in Taiwan.

Author information

1
From the Division of Pediatric Hematology and Oncology (C-YL, H-JY, C-CC, G-YH), Department of Pediatrics, Taipei Veterans General Hospital; School of Medicine (C-YL, C-CY, H-JY, C-YS, T-CC, P-KW, C-FC, PC-HC, H-THW, H-JC, C-CC, G-YH, W-MC), National Yang-Ming University; Therapeutical and Research Center of Musculoskeletal Tumor (C-YL, C-CY, H-JY, C-YS, T-CC, P-KW, C-FC, PC-HC, H-THW, H-JC, G-YH, W-MC), Department of Orthopedics; Division of Medical Oncology (C-CY, T-CC), Department of Oncology, Taipei Veterans General Hospital; Department of Life Science (H-JY, G-YH), National Taiwan Normal University; Division of Radiation Oncology (C-YS), Department of Oncology; Department of Orthopedics (P-KW, C-FC); Department of Pathology (PC-HC); Department of Radiology (H-THW, H-JC), Taipei Veterans General Hospital; National Defense Medical Center (H-JC), Taipei; Department of Pediatrics (C-CC), Taipei Veterans General Hospital Hsinchu Branch, Hsinchu; and Rehabilitation and Technical Aid Center (W-MC), Taipei Veterans General Hospital, Taipei, Taiwan.

Abstract

To identify the prognostic factors and long-term outcome of the Ewing sarcoma family of tumors (ESFT), data on 50 patients with ESFT treated at Taipei Veterans General Hospital between February 1991 and March 2014 were retrospectively considered. The influence of patient demographics, tumor features, and clinical and therapeutic parameters on overall survival (OS) and progression-free survival (PFS) rates were assessed. The results revealed that 21 of the 50 patients (42%) were metastatic at diagnosis. The median follow-up time was 1.8 years. The 5-year OS and PFS for patients who were nonmetastatic were 61.6% and 55.5%, respectively, and 18.8% and 15.4% for patients who were metastatic, respectively. The key adverse prognostic factor was metastasis at diagnosis. Radiotherapy for local control was associated with improved PFS. The high rate of primary metastasis and poorer outcomes of nonmetastatic ESFT compared with results from Western studies, along with previously reported low rates of ESFT in Taiwanese people, suggest that genetic factors play a role in the pathogenesis of ESFT and chemotherapy pharmacokinetics and pharmacodynamics. Radiotherapy in local treatment should be considered more aggressively in Taiwanese patients with ESFT.

PMID:
27258529
PMCID:
PMC4900737
DOI:
10.1097/MD.0000000000003830
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center